Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07135245) titled 'Improved Treatment and Monitoring of Alzheimer's Disease' on Aug. 4.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Rune Skovgaard Rasmussen

Condition: Alzheimer Disease (AD)

Intervention: Drug: Semaglutide (Rybelsus(R)) combined with other interventions Other: Placebo

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: January 1, 2026

Target Sample Size: 180

To know more, visit https://clinicalt...